{"id":"NCT02489227","sponsor":"Coherus Biosciences, Inc.","briefTitle":"Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis","officialTitle":"A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2016-05-06","completion":"2017-03","firstPosted":"2015-07-02","resultsPosted":"2019-10-18","lastUpdate":"2020-04-08"},"enrollment":545,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"CHS-1420","otherNames":[]},{"type":"DRUG","name":"Adalimumab","otherNames":["Humira"]}],"arms":[{"label":"Humira (adalimumab)","type":"ACTIVE_COMPARATOR"},{"label":"CHS-1420","type":"EXPERIMENTAL"}],"summary":"This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.","primaryOutcome":{"measure":"Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12","timeFrame":"12 weeks","effectByArm":[{"arm":"Humira (Adalimumab)","deltaMin":203,"sd":null},{"arm":"CHS-1420","deltaMin":211,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":99,"countries":["United States","Bulgaria","Canada","Chile","Croatia","Estonia","Georgia","Israel","Italy","Latvia","Moldova","Poland","Russia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":274},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}